Novartis to Acquire Avidity Biosciences for US$12 Billion Novartis will buy Avidity Biosciences for US$12 billion, gaining its RNA-based therapeutic platform and rare-disease programmes.
Canadian Lobbyists Represent Major Polluters and Environmental Groups A new report by FMinus reveals a conflict of interest in Canadian lo…
African Tax Leaders Meet to Discuss Wealthy Taxation The taxation of the wealthy is a key challenge for tax professionals and policymakers…
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK has acquired exclusive rights from Syndivia for an ADC targeting advanc…
Redefining Urban Living Through Harmony Between City and Nature The concept of "Tbilisi Acres" represents a modern urban settlement that c…
Grokipedia Launch and Controversy Elon Musk's Grokipedia, a rival to Wikipedia, has launched after a brief crash. The website, which claim…
Cygnet Energy Enters into Agreement to Acquire Kiwetinohk Energy Corp. Cygnet Energy Ltd., a private exploration and production company, h…
Two Killed in Funeral Shooting An intoxicated ex-resistance member opened fire at a funeral in Kanpetlet Township, killing a teenage stude…
Fraternity and Hope Strengthen Relations Between Catholics and Anglicans According to Archbishop Flavio Pace and Bishop Anthony Ball, the …
The Renters’ Rights Act Becomes Law The Renters’ Rights Act, which abolishes 'no-fault' evictions, aims to rebalance the relationship betw…
Building the Future, Respecting the Past Tbilisi is undergoing a dynamic transformation, with sustainable urban development taking center …